AUS
NZ
UK
CA
USA
IND
Cann Group (ASX:CAN), a pioneer in the medical cannabis sector, is signaling a turnaround after facing significant challenges. The company, which posted a $13.2 million loss for the 2023-24 financial year, is targeting a return to underlying earnings profitability within the current fiscal year. Additionally, Cann Group anticipates achieving cash-flow positivity by the 2025-26 period.
During a recent presentation at the Pitt Street Research life sciences conference in Sydney, Cann Group outlined a strategic plan to expand its Mildura facility's capacity to 10,000 tonnes annually by the 2026-27 timeframe. This facility, regarded as one of the most advanced indoor cannabis production sites in the southern hemisphere, is currently operating at only 20% of its capacity. The expansion aims to bolster revenue growth and profitability, leveraging the average selling price of $3.45 per gram.
Cann Group’s product range, including dried flowers, oils, vapes, and capsules, saw a 12% increase in revenue over the past year, reaching $15.73 million. Despite initial setbacks, including a $3.6 million scam and a temporary suspension of shares in March, the company’s fortunes are showing signs of recovery. The share suspension was lifted in June following the acquisition of a $5 million debt facility from a private credit source. Additionally, Cann Group has secured a $49.4 million construction facility and a $15.6 million working capital facility with the National Australia Bank, with loan maturities extended to May 2025 and November 2024, respectively.
Market data indicates that 2.24 million Australians consume approximately 650 tonnes of cannabis annually, both legally and illegally. The legal medical cannabis market, though smaller at around 100 tonnes annually, represents a significant and rapidly growing sector valued between $500 million and $700 million.
In other news, Opthea (ASX:OPT), a company specializing in eye disease treatments, has demonstrated progress in its drug development efforts. Opthea has successfully manufactured three consecutive commercial-scale batches of sozinibercept, a candidate drug for treating wet age-related macular degeneration (wet AMD). This achievement completes the Process Performance Qualification (PPQ) campaign, a critical step towards filing for a biologics license. The company’s Phase III trials, involving 2,000 patients, are advancing, and Opthea’s shares have recently risen by 6% to 70 cents, reflecting positive market sentiment towards its drug development progress.
Meanwhile, Singular Health Group (ASX:SHG) has taken strategic steps to streamline its operations. The company has sold a non-core 3D printing business, generating $450,000 and securing a rent-free deal for its Perth premises. This move allows Singular Health to focus on its core product, 3Dicom, a software solution designed to enhance the visualization and communication of medical images. The transaction provides $250,000 upfront, with an additional $200,000 in vendor finance repayable within 12 to 14 months. The cost-saving aspect of the deal, which eliminates $100,000 in annual rent and reduces outgoings, is expected to support Singular Health’s financial stability. Following these developments, Singular Health’s shares have gained 2% to 9.2 cents.
These updates highlight significant shifts and advancements within the medical and health sectors, as companies navigate challenges and capitalize on new opportunities.
